Mga Batayang Estadistika
| LEI | 213800K5NF92PPHPA304 |
| CIK | 1709626 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NuCana plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal ex |
|
| September 5, 2025 |
NuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029 EX-99.1 Exhibit 99.1 NuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, September 5, 2025 (GLOBE NEWSWIRE) - NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable N |
|
| September 3, 2025 |
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 EX-99.1 Exhibit 99.1 NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 EDINBURGH, United Kingdom, September 3, 2025 (GLOBE NEWSWIRE) - NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Cong |
|
| September 3, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal ex |
|
| August 20, 2025 |
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2025 2024 2025 2024 (in thousands, except per share data) £ £ £ £ Research and development expenses (7,104 ) (6,769 ) (8,829 ) (13,552 ) Administrative expenses (4,523 ) (1,509 ) (5,590 ) (3,090 ) Net foreign exchange (losses) gains (202 ) (7 |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| August 20, 2025 |
EX-99.3 Exhibit 99.3 NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in |
|
| August 20, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securit |
|
| August 1, 2025 |
NuCana Announces ADS Ratio Change EX-99.1 Exhibit 99.1 NuCana Announces ADS Ratio Change Edinburgh, United Kingdom, August 1, 2025 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company’s previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to on |
|
| August 1, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive off |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) I |
|
| July 21, 2025 |
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution EX-99.1 Exhibit 99.1 NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution Edinburgh, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of |
|
| July 16, 2025 |
As filed with the Securities and Exchange Commission on July 16, 2025 Registration No. |
|
| July 16, 2025 |
Exhibit (a)(i) AMENDMENT NO. 1 TO AMENDED AND RESTATED DEPOSIT AGREEMENT by and among NUCANA PLC AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [l], 2025 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Effective Date 1 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 De |
|
| July 16, 2025 |
Exhibit (a)(ii) AMENDED AND RESTATED DEPOSIT AGREEMENT by and among NUCANA PLC and CITIBANK, N. |
|
| July 11, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| July 11, 2025 |
NuCana Announces Plan to Implement ADS Ratio Change Exhibit 99.1 NuCana Announces Plan to Implement ADS Ratio Change Edinburgh, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordi |
|
| July 9, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| June 30, 2025 |
NUCANA PLC AMERICAN DEPOSITARY SHARES SALES AGREEMENT Exhibit 1.1 NUCANA PLC AMERICAN DEPOSITARY SHARES SALES AGREEMENT June 27, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue New York, NY 10175 Ladies and Gentlemen: NuCana plc, a public limited company organized under the laws of England and Wales (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance G |
|
| June 30, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| June 27, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| June 27, 2025 |
NuCana plc American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281576 PROSPECTUS SUPPLEMENT (To prospectus dated June 24, 2025) NuCana plc $100,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., and Laidlaw & Company (UK) Ltd., or Laidlaw, relating to the sal |
|
| June 27, 2025 |
EX-10.1 Exhibit 10.1 June 17, 2025 NuCana plc 3 Lochside Way Edinburgh, EH12 9DT United Kingdom Attention: Hugh S. Griffith Re: Letter Agreement Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of May 5, 2025 (the “Purchase Agreement”), by and between NuCana plc (the “Company”) and the undersigned (each, an “Investor” and collectively, the “Invest |
|
| June 20, 2025 |
NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom CORRESP NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom June 20, 2025 VIA EDGAR U. |
|
| June 20, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executi |
|
| June 18, 2025 |
Exhibit 4.2 AMENDED AND RESTATED DEPOSIT AGREEMENT by and among NUCANA PLC and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of May 7, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Se |
|
| June 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 NuCana plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value £0. |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025 F-3/A Table of Contents As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. |
|
| June 18, 2025 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| June 5, 2025 |
NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 Exhibit 99.1 Notice of 2025 Annual General Meeting Friday, 27th June 2025 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 2 NOTICE OF 2025 ANNUAL GENERAL MEETING NOTICE OF 2025 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2025 annual general meeting of NuCana plc (the “Company”) wil |
|
| June 5, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executi |
|
| June 5, 2025 |
Exhibit 99.2 Directors Registered Office Hugh Griffith 77-78 Cannon Street Andrew Kay London Bali Muralidhar EC4N 6AF Martin Mellish U.K. Adam George (retired 21 March 2025) Cyrille Leperlier Global Headquarters Elliott Levy Lochside House 3 Lochside Way Secretary Edinburgh Martin Quinn EH12 9DT U.K. Auditors E: [email protected] Ernst & Young LLP www.nucana.com 144 Morrison Street Edinburgh EH3 8EX |
|
| June 2, 2025 |
Exhibit 99.3 SUPPLEMENTAL RISK FACTORS Investing in our securities involves a high degree of risk. You should carefully consider the risks described under “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission (“SEC”), and all other information contained in, or incorporated by reference in, our filings |
|
| June 2, 2025 |
Exhibit 99.4 NuCana Reports First Quarter 2025 Financial Results and Provides Business Update Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pe |
|
| June 2, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| June 2, 2025 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2025 2024 (in thousands, except per share data) £ £ Research and development expenses (1,725 ) (6,783 ) Administrative expenses (1,067 ) (1,581 ) Net foreign exchange (losses) gains (59 ) 95 Operating loss (2,851 ) (8,269 ) Finance income 25 126 Loss before tax (2,826 ) (8,1 |
|
| June 2, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| May 7, 2025 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Number 333-286716 PROSPECTUS NuCana plc 2,452,935 American Depositary Shares Representing 61,323,375 Ordinary Shares Series A Warrants to Purchase up to 10,845,985 American Depositary Shares Representing up to 271,149,625 Ordinary Shares Series B Warrants to Purchase up to 10,845,985 American Depositary Shares Representing up to |
|
| May 5, 2025 |
CORRESP May 5, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NuCana plc Registration Statement on Form F-1, as amended File No. 333-286737 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “ |
|
| May 5, 2025 |
NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom CORRESP NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom May 5, 2025 VIA EDGAR U. |
|
| May 2, 2025 |
SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 Exhibit 4.7 SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES A ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “Initial |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025. Table of Contents As filed with the Securities and Exchange Commission on May 1, 2025. |
|
| May 2, 2025 |
SERIES B WARRANT LOCK-UP AGREEMENT Exhibit 10.17 SERIES B WARRANT LOCK-UP AGREEMENT This Series B Warrant Lock-Up Agreement (this “Agreement”) is dated as of April [ ], 2025, between NuCana plc, a public limited company organized under the laws of the England and Wales (the “Company”), and you, as the purchaser identified on the signature page hereto (including its successors and assigns, a “Holder”. Capitalized terms used and not |
|
| May 2, 2025 |
Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [•], 2025, between NuCana plc, a public limited company organized under the laws of the England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHE |
|
| May 2, 2025 |
EX-1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT April [•], 2025 Hugh Griffith Chief Executive Officer NuCana plc 3 Lochside Way Edinburgh, EH12 9DT United Kingdom Dear Mr. Griffith: This letter agreement (the “Agreement”) constitutes the agreement between Laidlaw & Company (UK) Ltd. (“Laidlaw”), as placement agent (the “Placement Agent”) and NuCana plc, a company incorporated under the laws of Engla |
|
| May 2, 2025 |
SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 Exhibit 4.8 SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES B ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “Initial |
|
| May 1, 2025 |
CORRESP May 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NuCana plc Registration Statement on Form F-1, as amended File No. 333-286737 Withdrawal of Request for Acceleration of Effective Date Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on April 29, 2025, in which |
|
| May 1, 2025 |
NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom CORRESP NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom May 1, 2025 VIA EDGAR U. |
|
| April 29, 2025 |
NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom CORRESP NUCANA PLC 3 Lochside Way Edinburgh, EH12 9DT United Kingdom April 29, 2025 VIA EDGAR U. |
|
| April 29, 2025 |
CORRESP1 One Financial Center Boston, MA 02111 617 542 6000 mintz.com April 29, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky and Tim Buchmiller Re: NuCana plc Registration Statement on Form F-1 Filed on April 24, 2025 CIK No. 0001709626 Ladies and Gentlemen: W |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025. Table of Contents As filed with the Securities and Exchange Commission on April 29, 2025. |
|
| April 29, 2025 |
SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 Exhibit 4.7 SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES A ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “Initial |
|
| April 29, 2025 |
CORRESP April 29, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NuCana plc Registration Statement on Form F-1, as amended File No. 333-286737 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (th |
|
| April 29, 2025 |
SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 Exhibit 4.8 SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES B ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “Initial |
|
| April 29, 2025 |
SERIES B WARRANT LEAK-OUT AGREEMENT Exhibit 10.17 SERIES B WARRANT LEAK-OUT AGREEMENT This Series B Warrant Leak-Out Agreement (this “Agreement”) is dated as of April [ ], 2025, between NuCana plc, a public limited company organized under the laws of the England and Wales (the “Company”), and you, as the purchaser identified on the signature page hereto (including its successors and assigns, a “Holder”. Capitalized terms used and no |
|
| April 29, 2025 |
Exhibit 4.6 PRE-FUNDED ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Initial Exercise Date: April [•], 2025 THIS PRE-FUNDED ADS PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| April 29, 2025 |
Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [•], 2025, between NuCana plc, a public limited company organized under the laws of the England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHE |
|
| April 29, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT April [•], 2025 Hugh Griffith Chief Executive Officer NuCana plc 3 Lochside Way Edinburgh, EH12 9DT United Kingdom Dear Mr. Griffith: This letter agreement (the “Agreement”) constitutes the agreement between Laidlaw & Company (UK) Ltd. (“Laidlaw”), as placement agent (the “Placement Agent”) and NuCana plc, a company incorporated under the laws of England and |
|
| April 24, 2025 |
Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [•], 2025, between NuCana plc, a public limited company organized under the laws of the England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHE |
|
| April 24, 2025 |
Exhibit (d) April 24, 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement, dated as of October 2, 2017, by and among Citibank, N.A., as Deposita |
|
| April 24, 2025 |
Exhibit (a)(ii) AMENDMENT NO. 1 TO DEPOSIT AGREEMENT by and among NUCANA PLC AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of April 16, 2024 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions. 1 Section 1.2 Effective Date. 1 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 Deposit Agreeme |
|
| April 24, 2025 |
Exhibit 4.4 AMENDED AND RESTATED DEPOSIT AGREEMENT by and among NUCANA PLC and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [•], 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Sect |
|
| April 24, 2025 |
EX-4.6 Exhibit 4.6 PRE-FUNDED ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Initial Exercise Date: April [•], 2025 THIS PRE-FUNDED ADS PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “I |
|
| April 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) NUCANA PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary Shares, nominal value £0. |
|
| April 24, 2025 |
EX-4.3 Exhibit 4.3 AMENDMENT NO. 1 TO DEPOSIT AGREEMENT by and among NUCANA PLC AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of April 16, 2024 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Effective Date 1 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 Deposit Agreem |
|
| April 24, 2025 |
EX-1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT April [•], 2025 Hugh Griffith Chief Executive Officer NuCana plc 3 Lochside Way Edinburgh, EH12 9DT United Kingdom Dear Mr. Griffith: This letter agreement (the “Agreement”) constitutes the agreement between Laidlaw & Company (UK) Ltd. (“Laidlaw”), as placement agent (the “Placement Agent”) and NuCana plc, a company incorporated under the laws of Engla |
|
| April 24, 2025 |
SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 EX-4.7 Exhibit 4.7 SERIES A ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES A ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “ |
|
| April 24, 2025 |
ARTICLES OF ASSOCIATION NUCANA PLC adopted by special resolution passed on 23 April 2025 EX-3.1 Exhibit 3.1 ARTICLES OF ASSOCIATION OF NUCANA PLC adopted by special resolution passed on 23 April 2025 CONTENTS Articles Page 1. EXCLUSION OF OTHER REGULATIONS 1 2. DEFINITIONS AND INTERPRETATION 1 3. LIABILITY OF MEMBERS 4 4. SHARE CAPITAL 4 5. VARIATION OF RIGHTS 6 6. ALTERATION OF CAPITAL 6 7. SHARE CERTIFICATES 7 8. CALLS ON SHARES 8 9. LIEN ON SHARES 9 10. FORFEITURE AND SURRENDER OF |
|
| April 24, 2025 |
As filed with the Securities and Exchange Commission on April 23, 2025. F-1 Table of Contents As filed with the Securities and Exchange Commission on April 23, 2025. |
|
| April 24, 2025 |
Exhibit (a)(i) AMENDED AND RESTATED DEPOSIT AGREEMENT by and among NUCANA PLC and CITIBANK, N. |
|
| April 24, 2025 |
SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 EX-4.8 Exhibit 4.8 SERIES B ADS PURCHASE WARRANT NUCANA PLC Warrant Shares: [•] Issuance Date: April [•], 2025 THIS SERIES B ADS PURCHASE WARRANT (“Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (such date, the “ |
|
| April 24, 2025 |
As filed with the Securities and Exchange Commission on April 24, 2025 Registration No. |
|
| April 24, 2025 |
DRSLTR One Financial Center Boston, MA 02111 617 542 6000 mintz.com April 23, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky and Tim Buchmiller Re: NuCana plc Draft Registration Statement on Form F-1 Submitted on April 4, 2025 CIK No. 0001709626 Ladies and Gent |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) |
|
| April 4, 2025 |
Table of Contents Confidential Treatment Requested by Nucana plc Pursuant to 17 C. |
|
| March 20, 2025 |
NUCANA PLC INSIDER TRADING POLICY TABLE OF CONTENTS Exhibit 19.1 NUCANA PLC INSIDER TRADING POLICY TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 2 II. What is Material Non-Public Information? 2 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading 5 Transactions by Family Members, Others in Your Household and Entities You Control 5 Other Companies’ Non-public Information 5 Personal or Independ |
|
| March 20, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian Webster, Director of Finance of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company for the p |
|
| March 20, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Hugh S. Griffith, Chief Executive Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company |
|
| March 20, 2025 |
Exhibit 12.2 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ian Webster, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fa |
|
| March 20, 2025 |
Exhibit 12.1 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Hugh S. Griffith, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| March 20, 2025 |
EX-99.1 Exhibit 99.1 NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Ph |
|
| March 20, 2025 |
Exhibit 4.16 22/39203 Books of Council and Session Extract Registered 28 Oct 2022 MINUTE OF VARIATION CUSTODIAN REIT PLC NUCANA PLC BRODIES LLP DX ED 10 EDINBURGH Registers of Scotland 22/39203 AT EDINBURGH the Twenty Eighth day of October Two thousand and twenty two the Deed hereinafter reproduced was presented for registration in the Books of the Lords of Council and Session for preservation and |
|
| March 20, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-281576) of NuCana plc and in the related Prospectus, (2) Registration Statement (Form S-8 No. 333-223476) pertaining to both NuCana BioMed Limited Option Share Schemes (Including Management Enterpri |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2025 |
Exhibit 97.1 NUCANA PLC CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of NuCana plc (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this polic |
|
| March 18, 2025 |
NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 Exhibit 99.1 Notice of General Meeting Monday, 7th April 2025 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 1 NOTICE OF GENERAL MEETING NOTICE is hereby given that a general meeting of NuCana plc (the “Company”) will be held on 7 April 2025 at 11.00am at Lochside House, 3 Lochside Way, Edinb |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| February 14, 2025 |
EX-99.1 2 tm256670d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares of NuCana plc and further agree that this agreement be included as a |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executi |
|
| November 25, 2024 |
Exhibit 99.3 NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024 Announced Promising Phase 1b/2 Data on NUC-3373 in Combination with Pembrolizumab or Docetaxel Anticipated Cash Runway into Q2 2025 Edinburgh, United Kingdom, |
|
| November 25, 2024 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2024 2023 2024 2023 (in thousands, except per share data) £ £ £ £ Research and development expenses (3,736 ) (7,439 ) (17,288 ) (18,203 ) Administrative expenses (1,358 ) (1,375 ) (4,448 ) (4,777 ) Net foreign exchange (losses) gai |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executi |
|
| November 25, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| November 12, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal exe |
|
| November 12, 2024 |
Exhibit 99.1 NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab One Pat |
|
| October 1, 2024 |
NuCana plc Up to $5,407,000 American Depositary Shares representing Ordinary Shares 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-258941 AMENDMENT NO. 2 DATED SEPTEMBER 30, 2024 to Prospectus Supplement dated August 27, 2021, as amended on March 27, 2024 (To Prospectus dated August 27, 2021) NuCana plc Up to $5,407,000 American Depositary Shares representing Ordinary Shares This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends our prospectus supple |
|
| October 1, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal ex |
|
| September 26, 2024 |
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States Exhibit 99.1 NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States Edinburgh, United Kingdom, September 25, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is expected to serve as a key component o |
|
| September 26, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal ex |
|
| September 16, 2024 |
EX-99.1 Exhibit 99.1 NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile Barcelona, Spain, September |
|
| September 16, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal ex |
|
| August 29, 2024 |
Exhibit 99.1 NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303 Studies Continue Unchanged with Encouraging Data on NUC-7738 plus Pembrolizumab to be Presented at the ESMO Annual Conference in September Edinburgh, United Kingdom, Au |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| August 15, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securit |
|
| August 15, 2024 |
As filed with the Securities and Exchange Commission on August 15, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 15, 2024 Registration No. |
|
| August 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 NuCana plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value £0. |
|
| August 15, 2024 |
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2024 2023 2024 2023 (in thousands, except per share data) £ £ £ £ Research and development expenses (6,769 ) (3,959 ) (13,552 ) (10,764 ) Administrative expenses (1,509 ) (1,754 ) (3,090 ) (3,402 ) Net foreign exchange (losses) gains (74 ) (5 |
|
| August 15, 2024 |
NUCANA PLC [ ] Trustee Dated as of [ ] Subordinated Debt Securities Exhibit 4.8 NUCANA PLC Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) |
|
| August 15, 2024 |
Exhibit 4.3 AMENDMENT NO. 1 TO DEPOSIT AGREEMENT by and among NUCANA PLC AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of April 16, 2024 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Effective Date 2 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 Deposit Agreement |
|
| August 15, 2024 |
Exhibit 99.3 NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 Edinburgh, United Kingdom, August 15, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development |
|
| August 15, 2024 |
NUCANA PLC Dated as of [ ] Senior Debt Securities Exhibit 4.7 NUCANA PLC Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5.04(b) |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) I |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) In |
|
| May 16, 2024 |
Exhibit 99.3 NuCana Reports First Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 |
|
| May 16, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| May 16, 2024 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2024 2023 (in thousands, except per share data) £ £ Research and development expenses (6,783 ) (6,805 ) Administrative expenses (1,581 ) (1,648 ) Net foreign exchange gains (losses) 95 (695 ) Operating loss (8,269 ) (9,148 ) Finance income 126 287 Loss before tax (8,143 ) (8 |
|
| May 13, 2024 |
NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 EX-99.1 Exhibit 99.1 Notice f 2024 Annual General Meeting Tuesday, 18th June 2024 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2024 ANNUAL GENERAL MEETING NOTICE OF 2024 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2024 annual general meeting of NuCana plc (the “Company |
|
| May 13, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executiv |
|
| May 13, 2024 |
Exhibit 99.2 Annual Report 2023 for the year ended 31 December 2023 Directors Registered Office Hugh Griffith 77-78 Cannon Street Andrew Kay London Bali Muralidhar EC4N 6AF Martin Mellish U.K. Adam George Cyrille Leperlier Global Headquarters Elliott Levy Lochside House 3 Lochside Way Secretary Edinburgh Martin Quinn EH12 9DT U.K. Auditors E: [email protected] Ernst & Young LLP www.nucana.com 144 Mo |
|
| May 1, 2024 |
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom, May 1, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has reg |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive of |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) |
|
| April 16, 2024 |
NuCana Announces Completion of ADS Ratio Change Exhibit 99.1 NuCana Announces Completion of ADS Ratio Change Edinburgh, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced that the Company’s previously disclosed plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary s |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| April 9, 2024 |
Exhibit 99.1 NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the Regulation of Genes Critical for Cancer Growth and Survival San Diego, Cali |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) |
|
| March 27, 2024 |
Exhibit (a)(i) AMENDMENT NO. 1 TO DEPOSIT AGREEMENT by and among NUCANA PLC AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [l], 2024 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions. 1 Section 1.2 Effective Date. 1 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 Deposit Agreement Ame |
|
| March 27, 2024 |
NuCana Announces Plan to Implement ADS Ratio Change Exhibit 99.1 NuCana Announces Plan to Implement ADS Ratio Change Edinburgh, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the “ADS Ratio”). The change |
|
| March 27, 2024 |
Exhibit (b)(ii) NuCana plc As of July 31, 2018 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Restricted ADSs /Affiliate (CUSIP No.: 67022C999) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of October 2, 2017, as amended and supplemented from time to time (the “Deposit Agreement”), by and among NuCana plc, a public limited company incorpo |
|
| March 27, 2024 |
Exhibit (b)(i) NUCANA PLC April 6, 2020 Citibank, N.A. – ADR Department 388 Greenwich Street New York, NY 10013 Attn: Ryan Everett Program ADSs (CUSIP No.: 67022C106) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of October 2, 2017, as amended and supplemented from time to time (the “Deposit Agreement”), by and among NuCana plc, a public limited company incorporated un |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
NuCana plc Up to $7,250,000 American Depositary Shares representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-258941 AMENDMENT NO. 1 DATED MARCH 27, 2024 to Prospectus Supplement dated August 27, 2021 (To Prospectus dated August 27, 2021) NuCana plc Up to $7,250,000 American Depositary Shares representing Ordinary Shares This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated August 27, 2021 (the “Prospec |
|
| March 27, 2024 |
Exhibit (a)(ii) DEPOSIT AGREEMENT by and among NuCana PLC and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of October 2, 2017 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 1 Section 1.4 “America |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office) |
|
| March 20, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald Munoz, Chief Financial Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company for |
|
| March 20, 2024 |
Exhibit 99.1 NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Pipeline Continues to Advance with Key Data Readouts Expected for All Programs in 2024 Randomized Phase 2 Study of 171 Second-Line Colorectal Cancer Patients Fully Recruited Anticipated Cash |
|
| March 20, 2024 |
Exhibit 12.1 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Hugh S. Griffith, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| March 20, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-258941) of NuCana plc and in the related Prospectus, (2) Registration Statement (Form S-8 No. 333-223476) pertaining to both NuCana BioMed Limited Option Share Schemes (Including Management Enterpri |
|
| March 20, 2024 |
Exhibit 4.16 22/39203 Books of Council and Session Extract Registered 28 Oct 2022 MINUTE OF VARIATION CUSTODIAN REIT PLC NUCANA PLC BRODIES LLP DX ED 10 EDINBURGH Registers of Scotland 22/39203 AT EDINBURGH the Twenty Eighth day of October Two thousand and twenty two the Deed hereinafter reproduced was presented for registration in the Books of the Lords of Council and Session for preservation and |
|
| March 20, 2024 |
Exhibit 97.1 NUCANA PLC CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of NuCana plc (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this polic |
|
| March 20, 2024 |
Exhibit 12.2 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Donald Munoz, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 20, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Hugh S. Griffith, Chief Executive Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company |
|
| February 27, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* NuCana plc (Name of Issuer) American Depositary Shares representing Ordinary Shares, nominal value £0.04 per share (Title of Class of Securities) 67022C106 (CUSIP Numb |
|
| February 14, 2024 |
NCNA / NuCana plc - Depositary Receipt (Common Stock) / Griffith Hugh - SC 13G/A Passive Investment SC 13G/A 1 d778712dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* NUCANA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 16, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principa |
|
| November 16, 2023 |
EX-99.4 Exhibit 99.4 NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, November 16, 2023 (GLOBE NE |
|
| November 16, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securit |
|
| November 16, 2023 |
EX-99.1 Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2023 2022 2023 2022 (in thousands, except per share data) £ £ £ £ Research and development expenses (7,439 ) (7,386 ) (18,203 ) (23,238 ) Administrative expenses (1,375 ) (1,715 ) (4,777 ) (5,756 ) Net foreign exchange gain |
|
| November 16, 2023 |
Exhibit 99.3 Supplemental Risk Factors Our business has significant risks. You should carefully consider the following risk factors and all other information contained in our Annual Report on Form 20-F for the year ended December 31, 2022 (our “Annual Report”) and in subsequent reports filed on Form 6-K, including our consolidated financial statements and the related notes. The risks and uncertain |
|
| November 13, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal exe |
|
| November 13, 2023 |
NuCana Announces Listing Transfer to Nasdaq Capital Market Exhibit 99.1 NuCana Announces Listing Transfer to Nasdaq Capital Market Edinburgh, United Kingdom, November 10, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Glob |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executiv |
|
| October 16, 2023 |
Exhibit 99.1 NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in Tumor Vol |
|
| October 13, 2023 |
EX-99.1 Exhibit 99.1 NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer P |
|
| October 13, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal exec |
|
| September 18, 2023 |
Exhibit 99.1 NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 Edinburgh, United Kingdom, September 18, 2023 (GLOBE NEWSWIRE)—NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in B |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal execut |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive |
|
| August 16, 2023 |
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2023 2022 2023 2022 (in thousands, except per share data) £ £ £ £ Research and development expenses (3,959 ) (6,406 ) (10,764 ) (15,852 ) Administrative expenses (1,754 ) (1,889 ) (3,402 ) (4,040 ) Net foreign exchange (losses) gains (564 ) 3 |
|
| August 16, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| August 16, 2023 |
EX-99.3 Exhibit 99.3 NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, August 16, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended Ju |
|
| June 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offic |
|
| May 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive office |
|
| May 17, 2023 |
Exhibit 99.3 NuCana Reports First Quarter 2023 Financial Results and Provides Business Update Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2023 and provided an update on its broad |
|
| May 17, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securit |
|
| May 17, 2023 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2023 2022 (in thousands, except per share data) £ £ Research and development expenses (6,805 ) (9,446 ) Administrative expenses (1,648 ) (2,152 ) Net foreign exchange (losses) gains (695 ) 1,131 Operating loss (9,148 ) (10,467 ) Finance income 287 31 Loss before tax (8,861 ) |
|
| May 15, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executiv |
|
| May 15, 2023 |
EX-99.2 Exhibit 99.2 Directors Registered Office Hugh Griffith 77-78 Cannon Street Andrew Kay London Bali Muralidhar EC4N 6AF Martin Mellish U.K. Adam George Cyrille Leperlier Global Headquarters Elliott Levy Lochside House James Healy (retired 27 April 2022) 3 Lochside Way Edinburgh Secretary EH12 9DT Martin Quinn U.K. E: [email protected] Auditors www.nucana.com Ernst & Young LLP 144 Morrison Stre |
|
| May 15, 2023 |
NOTICE OF 2023 ANNUAL GENERAL MEETING EX-99.1 Exhibit 99.1 NOTICE OF 2023 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2023 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2023 annual general meeting of NuCana plc (the “Company”) will be held on 15 June 2023 at 11.00am at Lochside House, 3 Lochside Way, Edinburgh EH12 9DT, U.K. for transaction of the followi |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive of |
|
| May 12, 2023 |
NuCana Announces Receipt of Nasdaq Notice EX-99.1 Exhibit 99.1 NuCana Announces Receipt of Nasdaq Notice Edinburgh, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 9, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositar |
|
| April 14, 2023 |
EX-99.1 Exhibit 99.1 NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer Activity in Highly Metabolic Tumors Orlando, Florida April 14, 2023 (GLOBE NEWS |
|
| April 14, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal execut |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 4, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Hugh S. Griffith, Chief Executive Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company |
|
| April 4, 2023 |
Exhibit 12.2 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Donald Munoz, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| April 4, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offi |
|
| April 4, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald Munoz, Chief Financial Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company for |
|
| April 4, 2023 |
Minute of Variation between the registrant and Custodian REIT PLC, dated October 27, 2022 Exhibit 14.6 22/39203 Books of Council and Session Extract Registered 28 Oct 2022 MINUTE OF VARIATION CUSTODIAN REIT PLC NUCANA PLC BRODIES LLP DX ED 10 EDINBURGH Registers of Scotland 22/39203 AT EDINBURGH the Twenty Eighth day of October Two thousand and twenty two the Deed hereinafter reproduced was presented for registration in the Books of the Lords of Council and Session for preservation and |
|
| April 4, 2023 |
Exhibit 12.1 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Hugh S. Griffith, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| April 4, 2023 |
EX-99.1 Exhibit 99.1 NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, April 4, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2022 and prov |
|
| April 4, 2023 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-258941) of NuCana plc and in the related Prospectus, (2) Registration Statement (Form S-8 No. 333-223476) pertaining to both NuCana BioMed Limited Option Share Schemes (Including Management Enterpri |
|
| March 24, 2023 |
EX-99.1 Exhibit 99.1 Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid Ruling Has No Impact on NuCana’s Anti-Cancer ProTide Patents Munich, Germany, March 24, 2023 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office |
|
| March 24, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal executive offi |
|
| February 13, 2023 |
NCNA / NuCana plc / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NuCana PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 13, 2023 |
NCNA / NuCana plc / Griffith Hugh - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* NUCANA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal exec |
|
| January 23, 2023 |
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement EX-99.1 Exhibit 99.1 NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom, January 23, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company th |
|
| January 6, 2023 |
NuCana Announces Receipt of NASDAQ Notice EX-99.1 2 d420113dex991.htm EX-99.1 Exhibit 99.1 NuCana Announces Receipt of NASDAQ Notice Edinburgh, United Kingdom, January 6, 2023 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 3, 2023, indicating that, based upon a closing bid price of less than $1.00 per share f |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executiv |
|
| November 16, 2022 |
For the Three Months Ended September 30, EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securit |
|
| November 16, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant’s principal exe |
|
| November 16, 2022 |
EX-99.1 Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2022 2021 2022 2021 (in thousands, except per share data) £ £ £ £ Research and development expenses (7,386 ) (8,971 ) (23,238 ) (26,200 ) Administrative expenses (1,715 ) (2,277 ) (5,756 ) (6,456 ) Net foreign exchange gain |
|
| November 16, 2022 |
EX-99.3 Exhibit 99.3 NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, November 16, 2022 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 3 |
|
| October 26, 2022 |
Exhibit 99.1 NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022 NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Barcelona, Spain, October 26, 2022 (GLOBE NEWSWIRE) ? NuCana plc (NA |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executiv |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal execut |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal execut |
|
| September 12, 2022 |
Exhibit 99.1 NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients Randomized Study of NUFIRI vs. FOLFIRI in Second-Line Colorectal Cancer Patients Initiated Paris |
|
| September 12, 2022 |
Exhibit 99.1 NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in Phase 2 Paris, France, September 12, 2022 (GLOBE NEWSWIRE) - NuCana plc (NASD |
|
| September 6, 2022 |
NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022 Exhibit 99.1 NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022 Edinburgh, United Kingdom, September 6, 2022 (GLOBE NEWSWIRE)?NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France. The details of NuCan |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal execut |
|
| August 17, 2022 |
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 (in thousands, except per share data) Notes ? ? ? ? Research and development expenses (6,406 ) (8,523 ) (15,852 ) (17,229 ) Administrative expenses (1,889 ) (2,075 ) (4,040 ) (4,179 ) Net foreign exchange gains (losses) 3,077 (1 |
|
| August 17, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| August 17, 2022 |
Exhibit 99.3 NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, August 17, 2022 (GLOBE NEWSWIRE) ? NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive |
|
| August 11, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| August 11, 2022 |
NCNA / NuCana plc / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NuCana plc (Name of Issuer) Ordinary Shares, nominal value ?0.04 per share (Title of Class of Securities) 67022C106 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Address and |
|
| August 11, 2022 |
Exhibit 2 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. |
|
| July 27, 2022 |
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) ? NuCana plc (NASDAQ: NCNA), (?NuCana? or the ?Company?), announced that it has received a written notification (the ?Notification Letter?) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (?Nasdaq?) informing the Company that it has r |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| July 11, 2022 |
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent Exhibit 99.1 German Court Rules that Gilead?s Sofosbuvir Infringes NuCana?s ?190 Patent Edinburgh, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the ?Court?) issued a judgement on July 7, 2022 that Gilead Sciences Ireland UC and Gilead Sciences GmbH (together, ?Gilead?) |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| June 10, 2022 |
Exhibit 99.1 NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors Edinburgh, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE)?NuCana plc (NASDAQ: NCNA) |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| June 3, 2022 |
NuCana Announces Receipt of NASDAQ Notice Exhibit 99.1 NuCana Announces Receipt of NASDAQ Notice Edinburgh, United Kingdom, June 3, 2022 (GLOBE NEWSWIRE) ? NuCana plc (NASDAQ: NCNA) announced that it received written notification (the ?Notification Letter?) from The Nasdaq Stock Market LLC (?Nasdaq?) dated May 27, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company?s American Depositary Share |
|
| June 2, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive o |
|
| June 2, 2022 |
Exhibit 99.3 NuCana Reports First Quarter 2022 Financial Results and Provides Business Update Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with Solid Tumors First Patients Enrolled in Phase 2 Study of NUC-7738 Multiple Data Readouts in 2022 Well Capit |
|
| June 2, 2022 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2022 2021 (in thousands, except per share data) ? ? Research and development expenses (9,446 ) (8,706 ) Administrative expenses (2,152 ) (2,104 ) Net foreign exchange gains (losses) 1,131 (677 ) Operating loss (10,467 ) (11,487 ) Finance income 31 24 Loss before tax (10,436 |
|
| May 23, 2022 |
NOTICE OF 2022 ANNUAL GENERAL MEETING Exhibit 99.1 NOTICE OF 2022 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2022 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2022 annual general meeting of NuCana plc (the ?Company?) will be held on 23 June 2022 at 11.00am at Lochside House, 3 Lochside Way, Edinburgh EH12 9DT, UK for transaction of the following busines |
|
| May 23, 2022 |
6-K 1 d344667d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant’s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant |
|
| April 27, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Hugh Griffith, Chief Executive Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company for |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive office) |
|
| April 27, 2022 |
Exhibit 99.1 NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer Extends Anticipated Cash Runway into 2025 Edinburgh, United Kingdom, April 27, 2022 (GLOBE NEWSWIRE) ? |
|
| April 27, 2022 |
As filed with the Securities and Exchange Commission on April 27, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 27, 2022 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-258941) of NuCana plc and in the related Prospectus, (2) Registration Statement (Form S-8 No. 333-223476) pertaining to both NuCana BioMed Limited Option Share Schemes (Including Management Enterpri |
|
| April 27, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald Munoz, Chief Financial Officer of NuCana plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of the Company for |
|
| April 27, 2022 |
Exhibit 12.1 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Hugh S. Griffith, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| April 27, 2022 |
Exhibit 12.2 Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Donald Munoz, certify that: 1. I have reviewed this annual report on Form 20-F of NuCana plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive |
|
| March 8, 2022 |
Exhibit 99.1 NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022 Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU NUC-3373 Did Not Generate Metabolites Associated with 5-FU Dose-Limiting Toxicities Edinburgh, United Kingd |
|
| March 2, 2022 |
Exhibit 99.1 NuCana Announces Update for Phase 3 Biliary Tract Cancer Study Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts and Dosing of First Patients in Phase 3 Colorectal Cancer Study Expected in 2022 NUC-7738 Entering Phase 2 Solid Tumor an |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executive |
|
| February 28, 2022 |
NCNA / NuCana plc / Sofinnova Venture Partners VIII, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* NuCana plc (Name of Issuer) American Depositary Shares representing Ordinary Shares, nominal value £0.04 per share (Title of Class of Securities) 67022C106 (CUSIP Numb |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executi |
|
| February 22, 2022 |
Exhibit 99.1 NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data from Either Interim Analysis May Support an |
|
| February 11, 2022 |
NCNA / NuCana plc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NuCana PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
NCNA / NuCana plc / Griffith Hugh - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* NUCANA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 11, 2022 |
NCNA / NuCana plc / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* NuCana PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) 67022C106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 18, 2021 |
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2021 2020 2021 2020 (in thousands, except per share data) ? ? ? ? Research and development expenses (8,971 ) (6,117 ) (26,200 ) (17,918 ) Administrative expenses (2,277 ) (1,906 ) (6,456 ) (5,144 ) Net foreign exchange gains (losse |
|
| November 18, 2021 |
Exhibit 99.3 NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additional Encouraging Clinical Data for NUC-3373 a |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 (Commission File No. 001-38215) NUCANA PLC (Translation of registrant?s name into English) 3 Lochside Way Edinburgh EH12 9DT United Kingdom (Address of registrant?s principal executi |
|
| November 18, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and |
|
| November 1, 2021 |
Exhibit 99.1 NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana Edinburgh, United Kingdom, November 1, 2021 (GLOBE NEWSWIRE) ? NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for pati |
